MediGene

Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications

Retrieved on: 
Wednesday, February 1, 2023
FSE, Master of Business Administration, Business administration, Head, IPO, Corporate communication, MediGene, International business, Applied science, AG, Management

--- end of press release ---

Key Points: 
  • MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today the appointment of Pamela Keck as Vice President, Head of Investor Relations and Corporate Communications.
  • “We are delighted to have Pamela join us and we look forward to her leadership for our investor relations and corporate communications initiatives."
  • Pamela brings more than 15 years’ experience as an investor relations and corporate communications professional.
  • Most recently, she held the position of Vice President of Corporate Communications & Investor Relations with neurocare group AG, where she supported the company in its financing and growth activities.

Medigene Receives $3 Million Milestone Payment from 2seventy bio

Retrieved on: 
Wednesday, January 18, 2023
JW, MAGE, Therapy, FSE, HKEX, TCR, Partnership, Patient, Pharmaceutical industry, MediGene

This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform.

Key Points: 
  • This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform.
  • 2seventy bio (Nasdaq: TSVT) recently announced the initiation of a strategic partnership with JW Therapeutics (HKEX: 2126) with an initial focus of the collaboration being the development of 2seventy bio’s MAGE-A4 cell therapy in mainland China, Hong Kong, and Macao.
  • “We are delighted that Medigene’s partnership with 2seventy bio, has led to the progress of cell therapies in China through 2seventy bio’s strategic alliance with JW Therapeutics,” said Dr. Selwyn Ho, Chief Executive Officer of Medigene.
  • “This alliance, and recent milestone payment to Medigene, further validate our end-to-end technology platform and its potential to deliver differentiated, best-in-class TCRs.

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Retrieved on: 
Friday, January 6, 2023
GW Pharmaceuticals, PowderJect, Therapy, RTI International, MediGene, Risk, Patient, University, Orexo, Pharmaceutical industry, Immunocore

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.

Key Points: 
  • James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.
  • He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Nasdaq listed company Lava Therapeutics N.V.
  • Douglas Thomson, CEO of Pneumagen, commented, "We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen.
  • James Noble added "I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Retrieved on: 
Friday, January 6, 2023
GW Pharmaceuticals, PowderJect, Therapy, RTI International, MediGene, Risk, Patient, University, Orexo, Pharmaceutical industry, Immunocore

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.

Key Points: 
  • James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.
  • He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Nasdaq listed company Lava Therapeutics N.V.
  • Douglas Thomson, CEO of Pneumagen, commented, "We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen.
  • James Noble added "I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.

Medigene Announces Strategy and Corporate Update

Retrieved on: 
Tuesday, November 15, 2022
Growth, Epitope, Head, TME, BioNTech, AML, Tissue, Risk, MB, Acute myeloid leukemia, MM, Corporate development, Partnership, Patient, Multiple myeloma, Antigen, FSE, Myelodysplastic syndrome, Tumor microenvironment, MDS, File, Q&A, Webcast, Neoplasm, CTA, CET, NY-ESO-1, Cell death, Research, TCR, Cell, Safety, Pharmaceutical industry, Management, Vaccine, MediGene

We are excited to announce this strategy and corporate update for Medigene, said Dr. Selwyn Ho, MB BS, Chief Executive Officer at Medigene.

Key Points: 
  • We are excited to announce this strategy and corporate update for Medigene, said Dr. Selwyn Ho, MB BS, Chief Executive Officer at Medigene.
  • To support our efforts, we continue to strengthen our leadership team and have appointed Mr. James Cornicelli as Head of Corporate Development and Strategy.
  • The company is accelerating our plans to identify a suitable strategic partner and will provide an update in due course.
  • The company will host a live conference call and webcast on its updated strategy on Wednesday, November 16, 2022, at 3 pm CET.

Cardior Appoints Axel-Sven Malkomes as Chief Financial Officer

Retrieved on: 
Thursday, November 3, 2022
Pharmaceutical, Health, Clinical Trials, Cardiology, Doctor of Philosophy, CFO, RNA, Technology, University of Bamberg, Kellogg School of Management, INSEAD, Therapy, Growth, Compliance, Heart, Merck, Deutsche Bank, Information technology, Industry, Degenerative disease, Barclays, Merck Group, Lehman Brothers, Knowledge, Northwestern University, Patient, University, Dresdner Bank, University of Science and Technology, CEO, Credit Suisse, Entrepreneurship, Medicine, Medication, Risk, CBO, RNA transfection, Donaldson, Lufkin & Jenrette, 3i, MD, Pharmaceutical industry, Management, MediGene

Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO).

Key Points: 
  • Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Axel-Sven Malkomes as Chief Financial Officer (CFO).
  • Mr. Malkomes brings to Cardior nearly 30 years of life science industry experience from executive roles, investment banking, healthcare investing, and corporate development positions.
  • His decades of experience in the industry, with a strong track record across the financial side of biotech, will be an important addition to our team.
  • Mr. Malkomes started his career in investment banking at a range of banking institutions, namely Dresdner Bank, Sal.

2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

Retrieved on: 
Thursday, October 27, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, TCR, TGF, U.S. Securities and Exchange Commission, MediGene, Peptide, Goal, Lymphatic system, Private Securities Litigation Reform Act, Sale, Translation, JW, Disease, Industry, FDA, Therapy, Patient, LinkedIn, Form 10-K, Company, Population, CAR, Research, HKEX, Annual report, TIME, Program, Cancer, Risk, Regeneron Pharmaceuticals, MAGE, Social media, Multiple myeloma, Security (finance), Twitter, Hope, Pharmaceutical industry, Vaccine, Risk management

JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China as well as the clinical development pathways.

Key Points: 
  • JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China as well as the clinical development pathways.
  • We are delighted to work with 2seventy bio to jointly develop the MAGE-A4 TCR program and potentially other assets in China, said Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics.
  • Under the terms of the agreement, 2seventy bio will grant JW Therapeutics a license for the MAGE-A4 cell therapy in the Chinese mainland, Hong Kong (China), and Macao (China).
  • Additionally, 2seventy bio may leverage the early clinical data generated under the collaboration to support development in other geographies.

VACCINE COMPANY MEDIGEN DOUBLES PRESENCE IN RIVERSIDE TECHNOLOGY PARK TO 12,000 SQUARE FEET OF SPACE WITH PLANS TO INCREASE VACCINE MANUFACTURING

Retrieved on: 
Friday, September 2, 2022
Interstate Highway System, Lease, Research, Vaccine, Infection, Frederick, Maryland, Goal, Multimedia, CDMO, MD, Interstate 70, Growth, Pandemic, Contract, Pharmaceutical industry, MediGene

FREDERICK, Md., Sept. 2, 2022 /PRNewswire/ -- Medigen, Inc. announced today that it is doubling the amount of space leased at Riverside Technology Park in Frederick, Maryland to 12,000 square feet, which represents the second time the biotech company has expanded its operations at 8420 Gas House Pike within the last 36 months. The company intends to increase its manufacturing workforce, with the additional space expected to optimize the company's proprietary vaccine pipeline development, as well as contract manufacturing services. Riverside Technology Park, developed and managed by St. John Properties, Inc. is a 70-acre business community situated between MD Route 26 and Interstate 70 on Monocacy Boulevard.

Key Points: 
  • The company intends to increase its manufacturing workforce, with the additional space expected to optimize the company's proprietary vaccine pipeline development, as well as contract manufacturing services.
  • Riverside Technology Park, developed and managed by St. John Properties, Inc. is a 70-acre business community situated between MD Route 26 and Interstate 70 on Monocacy Boulevard.
  • The new lease, which commenced this month, represents a 100% increase in the aggregate office, research, manufacturing, and flexible space to be used by Medigen's growing vaccine development and manufacturing operations.
  • Daniel Foit, Leasing Representative of St John Properties, said, "This space at Riverside Technology Park is highly-flexible and perfectly suited for the range of uses needed by Medigen.

DGAP-News: Rentschler Biopharma Expands Leadership Team with Senior-Level Hires

Retrieved on: 
Wednesday, August 10, 2022
Association, Industry, CEO, CDMO, MediGene, German Association for Housing, Urban and Spatial Development, Board of directors, Schering AG, Professional, Molecular biology, Knowledge, AG, Communication, Actavis, Government, Viatris, Falk, University of Bayreuth, Corporation, Henley Business School, Biotechnology, Biology, Business administration, University, Time, Novartis, Master of Business Administration, Organization, Federal Executive Boards, Management

Dr. Sabine Sydow, former Head of industry association vfa bio, joins Rentschler Biopharma as Chief of Staff

Key Points: 
  • Dr. Sabine Sydow, former Head of industry association vfa bio, joins Rentschler Biopharma as Chief of Staff
    Laupheim, Germany, August 10, 2022 Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is expanding its Leadership Team with two experienced leaders in the areas of strategy and law.
  • Dr. Sabine Sydow joined Rentschler Biopharma on July 1, 2022 and is supporting the Executive Board as Chief of Staff.
  • I am very pleased to join Rentschler Biopharma and to help shape the future of this innovative and forward-looking company.
  • In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, June 28, 2022
Patient, Strategic planning, GLOBE, COVID-19, Cancer, Immune system, Nasdaq, YouTube, Head, Degenerative disease, Knowledge, Social media, Therapy, Fred Hutchinson Cancer Research Center, Mergers and acquisitions, Euronext Growth, Merck Group, Rale, Barclays, CAR, U.S. Securities and Exchange Commission, Forward-looking statement, Translation, LinkedIn, University of Washington School of Medicine, Medical research, Vice, Glycogen storage disease, MediGene, Health care, AML, B-ALL, Acute myeloid leukemia, Technology, Private Securities Litigation Reform Act, Gene editing, NASDAQ, MM, Annual report, Merck & Co., Acute lymphoblastic leukemia, University, Securities & Exchange Commission of Pakistan, Multiple myeloma, Management, Pharmaceutical industry, Cellectis, Sanofi, Research

We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board.

Key Points: 
  • We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board.
  • As of today, Dr. Bergstrom will serve as Director of Cellectis Board.
  • Previously, Donald A Bergstrom, M.D., Ph.D., was appointed as a Board Observer on the Companys Board of Directors on November 4, 2021.
  • Dr. Bergstrom currently serves as Executive Vice President, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company.